Drug Information
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides coprophilus DSM 18228
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides coprophilus DSM 18228 (log2FC = -0.98; p = 0.02). | |||
|
Studied Microbe: Bacteroides fragilis ATCC43859
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides fragilis ATCC43859 (log2FC = -5.155; p = 0.016). | |||
|
Studied Microbe: Bacteroides fragilis HMW 610
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides fragilis HMW 610 (log2FC = -3.708; p = 0.0). | |||
|
Studied Microbe: Bacteroides fragilis str. 3397 T10
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides fragilis str. 3397 T10 (log2FC = -0.924; p = 0.011). | |||
|
Studied Microbe: Bacteroides fragilis str. 3986 T(B)9
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides fragilis str. 3986 T(B)9 (log2FC = -0.839; p = 0.018). | |||
|
Studied Microbe: Bacteroides fragilis str. DS-208
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides fragilis str. DS-208 (log2FC = -0.898; p = 0.011). | |||
|
Studied Microbe: Bacteroides ovatus ATCC 8483
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides ovatus ATCC 8483 (log2FC = -0.722; p = 0.009). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 3731
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides thetaiotaomicron 3731 (log2FC = -0.548; p = 0.045). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 7330
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides thetaiotaomicron 7330 (log2FC = -0.723; p = 0.009). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron VPI-5482
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides thetaiotaomicron VPI-5482 (log2FC = -0.663; p = 0.009). | |||
|
Studied Microbe: Bacteroides uniformis ATCC 8492
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides uniformis ATCC 8492 (log2FC = -0.694; p = 0.005). | |||
|
Studied Microbe: Pretovella copri DSM 18205
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Pretovella copri DSM 18205 (log2FC = -0.366; p = 0.04). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor mu (MOP) | Target Info | Antagonist | [7], [8] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1668). | |||
| REF 2 | Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use. J Manag Care Pharm. 2008 Mar;14(2):186-94. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 6 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 7 | OxyContin abuse and overdose. Postgrad Med. 2009 Mar;121(2):163-7. | |||
| REF 8 | Mu opioid receptor antagonists: recent developments. ChemMedChem. 2007 Nov;2(11):1552-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.